South Korea-Based Undbio Co., Ltd. + Proprietary Insulin; Maybe Biosimilars (someday)

On April 13, 2023, a South Korean biopharmaceutical company known as Undbio Co., Ltd.http://undbio.com/eng/ signed a lease with West Virginia University to build what it refers to as an insulin " manufacturing facility " in the city of Morgantown, WV (seehttps://www.wvgazettemail.com/business/undbio-planning-insulin-facility-in-morgantown/article_6b986775-6a2e-5ce5-b312-c423d79cbda2.html for more information). In all likelihood, that will be for what pharma refers to as a " fill& finish " facility, rather than one where temperature-controlled bioreactors are located.Meanwhile, a nonprofit drug company known as Civica, Inc. is set to sell biosimilars of insulin glargine, aspart and lispro as soon as 2024 which it says will be " manufactured " in neighboring Virginia in the town of Petersburg (located just outside the state capitol of Richmond). However, we know with certainty from the company ' s own press release (seehttps://www.businesswire.com/news/home/20220303005321/en/Civica-to-Manufacture-and-Distribute-Affordable-Insulin/ for more) that facility will actually be a " fill& finish " facility whereby already-cultured biopharmaceuticals made offshore by GeneSys Biologics in Hyderabad, India will be packaged into vials and pens and then distributed across the U.S.The Morgantown, WV facility acquired by Undbio was previously owned and operated by Mylan, which completed a merger in November 2020 with Pfizer Inc. ' s Upjohn unit to form a new company known as Viatris. ...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 morgantown west virginia wv mylan biosimilar insulin undbio Source Type: blogs